{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:18:36Z","timestamp":1760141916249,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2135"],"award-info":[{"award-number":["JPMJSP2135"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K06209"],"award-info":[{"award-number":["JP23K06209"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dmpk.2025.101486","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:55:28Z","timestamp":1746273328000},"page":"101486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats"],"prefix":"10.1016","volume":"62","author":[{"given":"Tomohiro","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moeko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-8514","authenticated-orcid":false,"given":"Arimi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-2304","authenticated-orcid":false,"given":"Takahiro","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4766-5830","authenticated-orcid":false,"given":"Hiroyuki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4799-7763","authenticated-orcid":false,"given":"Takahiro","family":"Ishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-7879","authenticated-orcid":false,"given":"Tsutomu","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-1532","authenticated-orcid":false,"given":"Yoshimichi","family":"Sai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2025.101486_bib1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(89)91014-3","article-title":"FK 506 for liver, kidney, and pancreas transplantation","volume":"2","author":"Starzl","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.dmpk.2025.101486_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.dmpk.2025.101486_bib3","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dmpk.2025.101486_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bmt.1703097","article-title":"Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation","volume":"28","author":"Hiraoka","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dmpk.2025.101486_bib5","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.dmpk.2025.101486_bib6","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood.V88.9.3634.bloodjournal8893634","article-title":"FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors","volume":"88","author":"Nash","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.dmpk.2025.101486_bib7","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/art.10427","article-title":"Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study","volume":"46","author":"Furst","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dmpk.2025.101486_bib8","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1002\/art.11363","article-title":"Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial","volume":"48","author":"Yocum","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dmpk.2025.101486_bib9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00007890-199405270-00022","article-title":"Fluconazole therapy in transplant recipients receiving FK506","volume":"57","author":"Ma\u00f1ez","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.dmpk.2025.101486_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(94)92383-3","article-title":"Interaction between tacrolimus and erythromycin","volume":"344","author":"Jensen","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.dmpk.2025.101486_bib11","first-page":"209","article-title":"Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes","volume":"82","author":"Iwasaki","year":"1993","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101486_bib12","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.46.9.3091-3093.2002","article-title":"Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes","volume":"46","author":"Venkataramanan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmpk.2025.101486_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.1996.tb00181.x","article-title":"Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes","volume":"41","author":"Christians","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101486_bib14","first-page":"1217","article-title":"Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients","volume":"59","author":"Furlan","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.dmpk.2025.101486_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2133\/dmpk.22.441","article-title":"Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient","volume":"22","author":"Takahashi","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2025.101486_bib16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0140-6736(93)90852-8","article-title":"FK 506 interaction with danazol","volume":"341","author":"Shapiro","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.dmpk.2025.101486_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.transproceed.2005.02.055","article-title":"High initial blood levels of tacrolimus in overweight renal transplant recipients","volume":"37","author":"Rodrigo","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmpk.2025.101486_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2133\/dmpk.DMPK-13-RG-110","article-title":"Mechanisms of lower maintenance dose of tacrolimus in obese patients","volume":"29","author":"Sawamoto","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2025.101486_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1432-2277.2001.tb00050.x","article-title":"Increased tacrolimus levels during diarrhea","volume":"14","author":"Hochleitner","year":"2001","journal-title":"Transpl Int"},{"key":"10.1016\/j.dmpk.2025.101486_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/00912700122009999","article-title":"Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101486_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0041-1345(98)00234-6","article-title":"Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation","volume":"30","author":"Undre","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmpk.2025.101486_bib22","first-page":"2763","article-title":"Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients","volume":"23","author":"Jain","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmpk.2025.101486_bib23","first-page":"2771","article-title":"Strategy of FK 506 therapy in liver transplant patients: effect of graft function","volume":"23","author":"Abu-Elmagd","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmpk.2025.101486_bib24","first-page":"57","article-title":"Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations","volume":"22","author":"Jain","year":"1990","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmpk.2025.101486_bib25","first-page":"3085","article-title":"Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration","volume":"23","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dmpk.2025.101486_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.dmpk.2025.101486_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/138920012802138598","article-title":"Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism","volume":"13","author":"Shen","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.dmpk.2025.101486_bib28","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dmpk.2025.101486_bib29","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dmpk.2025.101486_bib30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/0091270007306958","article-title":"Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check","volume":"47","author":"Seitz","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101486_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2009.308","article-title":"Therapeutic protein-drug interactions and implications for drug development","volume":"87","author":"Huang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101486_bib32","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1124\/dmd.114.058586","article-title":"Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates","volume":"42","author":"Han","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101486_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12272-015-0681-9","article-title":"A rapid and sensitive method to determine tacrolimus in rat whole blood using liquid-liquid extraction with mild temperature ultrasonication and LC-MS\/MS","volume":"39","author":"Park","year":"2016","journal-title":"Arch Pharm Res (Seoul)"},{"key":"10.1016\/j.dmpk.2025.101486_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1023\/A:1023294632129","article-title":"Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method","volume":"26","author":"Hisaka","year":"1998","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.dmpk.2025.101486_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/cs0680023","article-title":"Effect of two models of portal hypertension on splanchnic organ blood flow in the rat","volume":"68","author":"Lebrec","year":"1985","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.dmpk.2025.101486_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/00912700122010519","article-title":"Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101486_bib37","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","article-title":"Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer","volume":"69","author":"Girish","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101486_bib38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.dmpk.2025.101486_bib39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmpk.2025.101486_bib40","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1023\/A:1018967107612","article-title":"Oral absorption of FK506 in rats","volume":"10","author":"Kagayama","year":"1993","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmpk.2025.101486_bib41","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.clinthera.2014.02.021","article-title":"Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study","volume":"36","author":"Tsunashima","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.dmpk.2025.101486_bib42","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1124\/dmd.112.046169","article-title":"In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates","volume":"40","author":"Davis","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2025.101486_bib43","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/pharmaceutics12030220","article-title":"Mertansine inhibits mRNA expression and enzyme activities of cytochrome P450s and uridine 5\u2019-diphospho-glucuronosyltransferases in human hepatocytes and liver microsomes","volume":"12","author":"Choi","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmpk.2025.101486_bib44","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1158\/1535-7163.TARG-11-A136","article-title":"Abstract A136: nonclinical disposition, metabolism, and in vitro drug-drug interaction assessment of DM1, a component of trastuzumab emtansine (T-DM1)","volume":"10","author":"Wong","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.dmpk.2025.101486_bib45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/cpt.2448","article-title":"Risk-based pharmacokinetic and drug-drug interaction characterization of antibody-drug conjugates in oncology clinical development: an international consortium for innovation and quality in pharmaceutical development perspective","volume":"112","author":"Li","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2025.101486_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13058-016-0691-7","article-title":"Phase 1b\/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer","volume":"18","author":"Krop","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.dmpk.2025.101486_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12282-018-0887-z","article-title":"Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study","volume":"26","author":"Noguchi","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.dmpk.2025.101486_bib48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcph.116","article-title":"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies","volume":"53","author":"Han","year":"2013","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436725004367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436725004367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:16:57Z","timestamp":1760073417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436725004367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"alternative-id":["S1347436725004367"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2025.101486","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2025.101486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101486"}}